Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

17.05.23	Sanofi: Information concerning the total number of voting rights and shares – April 2023 (GlobeNewswire)
12.05.23	Sanofi: Nirsevimab Delivers 83% Reduction In RSV Infant Hospitalizations In Phase 3b Trial (RTTNews)
12.05.23	Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting (GlobeNewswire)
04.05.23	Sanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS (GlobeNewswire)
27.04.23	Press Release: Sanofi completes acquisition of Provention Bio, Inc. (GlobeNewswire)
27.04.23	Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC (GlobeNewswire)
26.04.23	Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc. (GlobeNewswire)
24.04.23	Sanofi Launches Hepatitis A Vaccine In U.K For Use In Children Aged 12 Months To 15 Yrs (RTTNews)
19.04.23	Sanofi: Information concerning the total number of voting rights and shares - March 2023 (GlobeNewswire)
11.04.23	Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements (GlobeNewswire)
11.04.23	Sanofi Refiles Premerger Notification And Report Form On Provention Bio Acquisition (RTTNews)
10.04.23	Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc. (GlobeNewswire)
10.04.23	Sobi To Streamline Nirsevimab Agreement (RTTNews)
04.04.23	Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia (GlobeNewswire)
30.03.23	Press Release: Availability of the Q1 2023 Memorandum for modelling purposes (GlobeNewswire)
23.03.23	Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial (GlobeNewswire)
21.03.23	Sanofi : EU Approves Dupixent To Treat Severe Atopic Dermatitis In Children (RTTNews)
21.03.23	Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis (GlobeNewswire)
18.03.23	Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis (GlobeNewswire)
17.03.23	Sanofi To Cut U.S. List Price Of Its Most-prescribed Insulin By 78% (RTTNews)
16.03.23	Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance (GlobeNewswire)
14.03.23	Information concerning the total number of voting rights and shares – February 2023 (GlobeNewswire)
13.03.23	Sanofi To Buy Provention Bio For Around $2.9 Bln In Cash (RTTNews)
13.03.23	Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) (GlobeNewswire)
07.03.23	Sanofi - Aventis: FDA Accepts, For Review, SBLA For Dupixent For Treatment Of CSU (RTTNews)
07.03.23	Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review (GlobeNewswire)
02.03.23	Sanofi : Phase 3 Study Of Altuviiio In Hemophilia A Meets Primary Endpoint (RTTNews)
02.03.23	Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A (GlobeNewswire)
01.03.23	FDA Approves Regeneron's Kevzara To Treat Inflammatory Rheumatic Disease (RTTNews)
24.02.23	ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS) (GlobeNewswire)
24.02.23	Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease (GlobeNewswire)
24.02.23	FDA Approves Sanofi's Hemophilia Drug (RTTNews)
23.02.23	Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection (GlobeNewswire)
15.02.23	Sanofi: Information concerning the total number of voting rights and shares – January 2023 (GlobeNewswire)
13.02.23	Sanofi Global Head Of R&D John Reed To Resign (RTTNews)
13.02.23	Press Release: Sanofi announces change in R&D leadership (GlobeNewswire)
03.02.23	Sanofi Q4 Profit Climbs, Sees Slower Earnings Growth In FY23; Stock Down (RTTNews)
03.02.23	Sanofi Q4 Profit Climbs; Sees Higher Earnings In FY23 - Quick Facts (RTTNews)
29.01.23	Biotech Stocks Facing FDA Decision In February 2023 (RTTNews)
27.01.23	Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent (RTTNews)
12.01.23	Sanofi Ventures Announces Multi-year Capital Commitment From Sanofi (RTTNews)
22.12.22	Regeneron : Positive Dupixent Phase 3 Results In Eosinophilic Esophagitis Published (RTTNews)
19.12.22	Sanofi, Innate Expand Collaboration For Natural Killer Cell Therapeutics In Oncology (RTTNews)
16.12.22	Regeneron: CHMP Recommends Dupixent For EU Approval To Treat Eosinophilic Esophagitis (RTTNews)
15.12.22	Regeneron, Sanofi: Dupixent Approved In EU For Prurigo Nodularis (RTTNews)
12.12.22	Sanofi Says Doesn't Intend To Make Offer For Horizon; But Amgen Reportedly In Advanced Talks (RTTNews)
01.12.22	Form 8.3 - The Vanguard Group, Inc.: Sanofi (EQS Group)
18.11.22	Sanofi : EC Oks Enjaymo For Treatment Of Hemolytic Anemia In Adult With Cold Agglutinin Disease (RTTNews)
17.11.22	Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease (GlobeNewswire)
11.11.22	Regeneron, Sanofi: CHMP Recommends Approval Of Dupixent In The EU (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
17:58		Handel in Europa: STOXX 50 schliesst im Minus
17:58		Schwacher Handel: SMI schliesst mit Verlusten
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		SPI-Handel aktuell: SPI zum Handelsende leichter
17:58		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
16:01		NASDAQ-Handel NASDAQ 100 schwächelt zum Start des Freitagshandels

18:01

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

17:58

Handel in Europa: STOXX 50 schliesst im Minus

17:58

Schwacher Handel: SMI schliesst mit Verlusten

17:58

Verluste in Europa: Euro STOXX 50 letztendlich leichter

17:58

SPI-Handel aktuell: SPI zum Handelsende leichter

17:58

Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels